Standard BioTools (LAB) Earnings Analysis

Standard BioTools (LAB) next reports earnings on 2026-08-10, consensus EPS -0.01 USD. Last quarter (2025-08-11) it beat with EPS -0.04 USD vs -0.04 USD est (0%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -3.27.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LAB next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.01 USD
Revenue estimate0.02B

LAB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-08-11-0.04 USD-0.04 USD0%Beat
2025-02-26-0.05 USD-0.07 USD+28.6%Beat
2024-10-30-0.05 USD-0.08 USD+37.5%Beat
2024-07-31-0.08 USD-0.06 USD-33.3%Miss

Beat rate: 3/4 (75%) over reported quarters with consensus data.

LAB valuation and analyst view

Trailing P/E-3.27
Trailing EPS-0.24236 USD
Price / book0.57
Dividend yield0.00%
Market cap0.33B
Analyst consensusBuy (6 buy / 4 hold / 0 sell)

Related research pages

Frequently asked questions

When is Standard BioTools (LAB)'s next earnings date?

Standard BioTools is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.01 USD and revenue estimate of 0.02B.

Did LAB beat earnings last quarter?

In its 2025-08-11 report, LAB posted EPS of -0.04 USD versus a -0.04 USD estimate — a beat of 0%.

What is LAB's earnings track record?

Over the last 4 reported quarters with consensus data, LAB beat estimates 3 times (75%).

What is LAB's current P/E ratio and EPS?

LAB trades at a trailing P/E of -3.27 on trailing EPS of -0.24235835982297876 USD.

What do analysts rate LAB?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell).